List view / Grid view
The European Medicines Agency will now review additional data on the efficacy, safety and quality of the COVID-19 Vaccine Janssen, deciding whether to approve the vaccine for use in the EU.
The Emergency Use Listing will allow doses of the COVID-19 vaccines to be distributed through COVAX, the WHO’s vaccine allocation facility.
Pfizer and BioNTech have agreed to supply the European Union with 200 million additional doses of COMIRNATY in 2021, making the total 500 million doses.
Effective supply chain management can cut costs, improve service and enhance company revenues; however, the pharma industry has historically been a slow adopter of leading-edge practices. Nikki Withers discussed the fundamentals of contemporary supply chain management with Ed Sweeney, Professor of Logistics and Systems at Aston University, who believes that…
The rolling review will assess CVnCoV’s efficacy and immunogenicity data as it becomes available, speeding the decision process for an eventual marketing authorisation application.
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) began two new reviews and wrote guidance for healthcare professionals on the potential side effects of Strimvelis, Venclyxto and Zolgensma.
Research suggests at least a fifth of the US population are resistant to receiving a COVID-19 vaccine, reports suggest this could be due to disinformation and safety concerns.
Preliminary data indicate that Zyesami reduces the length of hospital stay in critical COVID-19 patients treated with High Flow Nasal Cannula (HFNC) therapy or mechanical ventilation.
The Emergency Use Authorization (EUA) for bamlanivimab and etesevimab was based on a trial where the antibodies lowered risk of hospitalisation and death in COVID-19 patients.
Investment into vaccines based on broadly neutralising antibodies could allow pan-virus vaccines to be developed and stockpiled before the next pandemic, say researchers.
The ACTIV-3 sub-study will evaluate the safety and efficacy of the AZD7442 synthetic antibody combination in at least 150 participants with mild-to-moderate COVID-19.
In this article we discuss how the problems associated with glass vial packaging may disrupt COVID-19 vaccine distribution and explore some of the latest innovations to overcome it.
Peginterferon-lambda rapidly reduced non-hospitalised COVID-19 patients’ viral loads and expedited their recovery in a Phase II study.
Pharmaceutical counterfeiting brought to the fore, as more than 3,000 saline filled vials being sold as COVID-19 vaccines were seized in Chinese police raids.
COVAX has allocated 90 million doses of AstraZeneca’s COVID-19 vaccine and 320,000 doses of the Pfizer-BioNTech vaccine to African countries.
